FDA Approves Oral PCSK9 Inhibitor for Cholesterol Reduction

Why it matters locally: The approval of this new oral medication for cholesterol reduction offers an additional treatment option for the significant portion of Indiana's adult population managing hypercholesterolemia, potentially improving public health outcomes across the state.

WASHINGTON – The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. This medication represents the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Doctors will prescribe Lipfendra as an addition to diet and exercise regimens. The FDA's decision provides a new treatment option for individuals working to manage their cholesterol levels.